A potential new strategy for glaucoma cell replacement therapy has been identified by a multidisciplinary team led by researchers at the Schepens Eye Research

Biopharmaceutical company OKYO Pharma Limited has reported positive safety and efficacy results in its Phase 2 trial evaluating the safety and efficacy of OK-101

Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) has been granted

OShow24 in Sydney promises be a massive opportunity to discover all the latest trends in eyewear and eye care technology.